Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Cancer Therapies02:49

Cancer Therapies

10.3K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.3K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.8K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Machine Vision-Guided Microphysiological Platform With Automated Microfluidics Enables Longitudinal Biomarker Monitoring and Emulation of Translationally Relevant Exposure Scenarios.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Rapid antimicrobial susceptibility testing directly from positive blood cultures.

The Analyst·2026
Same author

A Comprehensive Assessment of the Causal Relationship between Atopic Conditions and Pancreatic Cancer Risk: A Two-Sample Mendelian Randomization Study.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

New through-the-needle brush for pancreatic cyst assessment: a randomized controlled trial.

iGIE : innovation, investigation and insights·2026
Same author

Integrated microoptical system for continuous fluorescence monitoring of microtissues.

Microsystems & nanoengineering·2025
Same author

Plug-and-Play Centrifuge-Only Device for Rapid Sepsis Diagnosis.

Advanced healthcare materials·2025

Related Experiment Video

Updated: Feb 27, 2026

Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
09:01

Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy

Published on: May 22, 2020

3.6K

[Nanoparticles for cancer therapy].

Matthias Löhr1, Wouter van der Wijngaart2, Björn Fagerberg3

  • 1Karolinska Institutet - CLINTEC K53 Stockholm, Sweden Karolinska Institutet - CLINTEC K53 Stockholm, Sweden.

Lakartidningen
|July 5, 2017
PubMed
Summary
This summary is machine-generated.

Nanoparticles show promise for cancer diagnosis and therapy, but clinical application lags behind experimental success. Few novel nanoparticle formulations have reached clinical use despite their potential.

More Related Videos

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

3.2K
A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
07:59

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

Published on: March 4, 2017

9.5K

Related Experiment Videos

Last Updated: Feb 27, 2026

Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
09:01

Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy

Published on: May 22, 2020

3.6K
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

3.2K
A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
07:59

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

Published on: March 4, 2017

9.5K

Area of Science:

  • Oncology
  • Nanomedicine
  • Drug Delivery

Background:

  • Nanoparticles offer significant potential in oncology for diagnosis, therapy, and theragnostics.
  • A notable gap exists between experimental nanoparticle research and clinical applications in cancer treatment.
  • Current clinical use of nanoparticles is limited, with some drug-releasing formulations approved for specific cancer types.

Purpose of the Study:

  • To review the current status and clinical translation of nanoparticles in cancer therapy.
  • To highlight the challenges and successes in developing nanoparticles for oncological applications.
  • To discuss the future prospects of advanced nanoparticle formulations in cancer care.

Main Methods:

  • Review of existing clinical studies and approved nanoparticle-based cancer therapies.
  • Analysis of nanoparticle formulations, including liposomes and albumin-bound nanoparticles.
  • Examination of specific applications such as gene-directed enzyme prodrug therapy (GDEPT) and trans-arterial chemo-embolization (TACE).

Main Results:

  • Limited clinical translation of cell-containing nanoparticles, with one notable exception using gene-directed enzyme prodrug therapy (GDEPT).
  • Several cell-free, drug-releasing nanoparticles are in clinical use, particularly for liver tumors (e.g., doxorubicin for TACE).
  • Liposomal formulations of paclitaxel and irinotecan have been utilized in pancreatic cancer, with nanoparticle-albumin-bound paclitaxel (NAB-paclitaxel) approved for first-line pancreatic cancer therapy.

Conclusions:

  • Nanoparticle-albumin-bound paclitaxel and liposomal irinotecan represent significant clinical advancements for pancreatic cancer.
  • Despite promising experimental data, the clinical adoption of novel nanoparticle formulations for cancer therapy remains slow.
  • Further research and clinical trials are essential to realize the full potential of advanced nanoparticles in oncology.